MARKET

PRQR

PRQR

ProQR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.100
-0.100
-2.38%
Closed 16:35 11/23 EST
OPEN
4.250
PREV CLOSE
4.200
HIGH
4.550
LOW
4.100
VOLUME
527.11K
TURNOVER
--
52 WEEK HIGH
10.98
52 WEEK LOW
3.600
MARKET CAP
205.59M
P/E (TTM)
-3.3006
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ProQR to Present at 3rd Annual Evercore ISI Virtual HealthCONx Conference
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 18, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that Company management will present during a fireside chat at the upcoming 3rd Annual Evercore ISI Virtual HealthCONx Conference. The presentation will be webcast live on December 2, 2020 at 3:55pm EST. The live and archived webcast of the presentation will be accessible from the “Investors & Media” section of ProQR’s website (www.proqr.com) under ‘Events’. The archived webcast will be available for approximately 30 days following the presentation date.About ProQRProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.*Since 2012*FORWARD-LOOKING STATEMENTSThis press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our participation in this conference. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law. ProQR Therapeutics N.V.Investor Contact: Sarah Kiely ProQR Therapeutics N.V. T: +1 617 599 6228 skiely@proqr.com or Hans Vitzthum LifeSci Advisors T: +1 617 535 7743 hans@lifesciadvisors.comMedia Contact: Alison Chen LifeSci Communications T: +1 646 876 4932 achen@lifescicomms.com
GlobeNewswire · 6d ago
How Is ProQR Therapeutics' (NASDAQ:PRQR) CEO Paid Relative To Peers?
Daniel de Boer has been the CEO of ProQR Therapeutics N.V. (NASDAQ:PRQR) since 2012, and this article will examine the...
Simply Wall St. · 6d ago
ProQR (PRQR) Reports Q3 Loss, Lags Revenue Estimates
ProQR (PRQR) delivered earnings and revenue surprises of -33.33% and -100.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 11/16 13:35
ProQR reports Q3 results
ProQR (PRQR): Q3 GAAP EPS of -€0.26.Other income of €0.25M.Cash and equivalents of €88.8M.Press Release
Seekingalpha · 11/16 12:14
ProQR Announces Virtual Presentations at American Academy of Ophthalmology (AAO)
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual poster presentations at the Annual Meeting of the American Academy of Ophthalmology (AAO) held November 13-15, 2020. ProQR’s presentationsPresentation title: Phase 1b/2 trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10 (LCA10)Presenter: Stephen R. Russell, MD, Professor and Director of Vitreoretinal Diseases and Surgery Service, Department of Ophthalmology and Visual Sciences, University of IowaDate: The poster presentation will be available on the AAO meeting portal starting November 11, 2020Presentation title: Full-field stimulus testing (FST) to assess sepofarsen patient response in Leber congenital amaurosis type 10 (LCA10)Presenter: Allen Ho, MD, Professor of Ophthalmology, Wills Eye Hospital, Thomas Jefferson UniversityDate: The poster presentation will be available on the AAO meeting portal starting November 11, 2020About Sepofarsen Sepofarsen (QR-110) is being evaluated in the pivotal Phase 2/3 Illuminate trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of Leber congenital amaurosis 10 due to the p.Cys998X mutation (also known as the c.2991+1655A>G mutation) in the CEP290 gene. The p.Cys998X mutation leads to aberrant splicing of the mRNA and non-functional CEP290 protein. Sepofarsen is designed to enable normal splicing, resulting in restoration of normal (wild type) CEP290 mRNA and subsequent production of functional CEP290 protein. Sepofarsen is intended to be administered through intravitreal injections in the eye and has been granted orphan drug designation in the United States and the European Union and received fast-track designation and rare pediatric disease designation from the FDA as well as access to the PRIME scheme by the EMA.About ProQR ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and autosomal dominant retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind. *Since 2012*FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such statements include those relating to our presentations at AAO. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.ProQR Therapeutics N.V.Investor Contact: Sarah Kiely ProQR Therapeutics N.V. T: +1 617 599 6228 skiely@proqr.com or Hans Vitzthum LifeSci Advisors T: +1 617 535 7743 hans@lifesciadvisors.com  Media Contact: Alison Chen LifeSci Communications T: +1 646 876 4932 achen@lifescicomms.com
GlobeNewswire · 11/02 12:00
ProQR Announces Virtual Presentations at Scientific Conferences
LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced virtual presentations at the Ophthalmology Futures
GlobeNewswire · 09/24 21:10
Jounce Therapeutics rallies on license deal with Gilead, Tracon Pharma follows, I-Mab, Kindred Biosciences among major losers
Gainers: Jounce Therapeutics (JNCE) +42%, TRACON Pharmaceuticals (TCON) +13.8%, Nano-X Imaging (NNOX) +13.6%, Athenex (ATNX) +11.5%, Surface Oncology (SURF) +8%.Losers: I-Mab (IMAB) -14.5%, Kindred Biosciences (KIN) -13.7%, ProQR Therapeutics (PRQR) -13%, Vaxart (VXRT) -12.9%, ADiTx Therapeutics (ADTX) -12.2%.
Seekingalpha · 09/01 14:57
ProQR reports Q2 results
ProQR (NASDAQ:PRQR): Q2 GAAP EPS of -€0.08. Other income of €8.67M (+1448.2% Y/Y). Cash and equivalents of €87.1M. Press Release
seekingalpha · 08/07 02:25
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PRQR. Analyze the recent business situations of ProQR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PRQR stock price target is 23.14 with a high estimate of 32.97 and a low estimate of 19.98.
EPS
Institutional Holdings
Institutions: 77
Institutional Holdings: 31.58M
% Owned: 62.98%
Shares Outstanding: 50.14M
TypeInstitutionsShares
Increased
11
324.56K
New
12
-477.76K
Decreased
18
942.35K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman - Supervisory/Independent Director
Dinko Valerio
Chairman - Management/Chief Executive Officer
Daniel De Boer
Chief Scientific Officer
Naveed Shams
Vice President/Director of Investor Relations/IR Contact Officer
Lisa Hayes
Independent Director/Supervisory Board
Bart Filius
Independent Director/Supervisory Board
Theresa Heggie
Independent Director/Supervisory Board
Alison Lawton
Independent Director/Supervisory Board
Antoine Papiernik
Independent Director/Supervisory Board
James Shannon
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About PRQR
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is transcribed from a mutated gene in order to restore the expression and function of normal, or wild-type protein. Its product candidates include QR-010, an RNA-based oligonucleotide for the treatment of cystic fibrosis (CF), QR-110, an oligonucleotide and for the treatment of Leber’s congenital amaurosis (LCA).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of ProQR Therapeutics NV stock information, including NASDAQ:PRQR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRQR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRQR stock methods without spending real money on the virtual paper trading platform.